Crescita Therapeutics Announces the Results of its Annual General and Special Meeting of Shareholders

LAVAL, QC, May 15, 2019 /PRNewswire/ - Crescita Therapeutics Inc. (TSX: CTX) (OTC US: CRRTF) (Crescita or the Company), a commercial dermatology company with a portfolio of non-prescription skincare and prescription drug products for the treatment and care of skin conditions, diseases and their symptoms, today announced the voting results from its 2019 Annual General and Special Meeting of Shareholders held at its corporate headquarters in Laval, Québec.

Election of Directors
The detailed results of the votes for director nominees listed in the Management Information Circular dated March 18, 2019 (the "Circular") are as follows:

                                  NUMBER OF SHARES          PERCENTAGE OF VOTES
                                                           CAST

            Director
             Nominees



     ===

               FOR    
           
       WITHHELD          FOR  
      
              WITHHELD

     ===

      Daniel N.
       Chicoine         7,456,570  587,320         92.7%                    7.3%

     ===

       David A.
       Copeland         7,465,703  578,187         92.8%                    7.2%

     ===

      Anthony E.
      Dobranowski       7,476,684  567,206         92.9%                    7.1%

     ===

       John C.
        London          7,451,239  592,651         92.6%                    7.4%

     ===

      Dr. Jean-
       François
       Tremblay         7,483,476  560,414         93.0%                    7.0%

     ===

        Thomas
       Schlader         7,483,400  560,490         93.0%                    7.0%

     ===

Appointment of External Auditors
Ernst and Young LLP were appointed as external auditors of the Corporation for the next year by a majority of the votes cast by the shareholders present, or represented by proxy, and the directors were authorized to determine their remuneration. The shareholders voted as follows:

                  Outcome              NUMBER OF SHARES                 PERCENTAGE OF VOTES
                                                                   CAST

           ===

                    FOR                WITHHELD              FOR 
          
                WITHHELD

           ===

        Ernst
        &
        Young
        LLP
        appointed         7,796,409 597,104             92.9%                         7.1%

    ===

Approval of Amendments to and Continuation of Crescita's Shareholder Rights Plan
The resolution to approve the amendments to and the continuation of Crescita's Shareholder Rights Plan, as described in the Circular, was approved by a majority of the votes cast by shareholders present at the meeting or by proxy, as follows:

              Outcome              NUMBER OF SHARES                 PERCENTAGE OF VOTES
                                                               CAST

     ===

                 FOR               WITHHELD              FOR 
          
                WITHHELD

     ===

      Shareholder
       Rights Plan
        approved      7,415,592 628,298             92.2%                         7.8%

     ===

About Crescita Therapeutics Inc.
Crescita (TSX: CTX and OTC US: CRRTF) is a publicly traded, Canadian commercial dermatology company with a portfolio of non-prescription skincare products for the treatment and care of skin conditions and diseases and their symptoms and prescription drug products for the treatment of pain. Crescita owns multiple proprietary drug delivery platforms that support the development of patented formulations that can facilitate the delivery of active drugs into or through the skin. For additional information, please visit www.crescitatherapeutics.com.

View original content to download multimedia:http://www.prnewswire.com/news-releases/crescita-therapeutics-announces-the-results-of-its-annual-general-and-special-meeting-of-shareholders-300850702.html

SOURCE Crescita Therapeutics Inc.